Radiotherapy Plus Immunotherapy in Oligometastatic NSCLC: Review Maps Path to Individualized Multimodal Care
核心洞察
A new narrative review examines how radiotherapy and immunotherapy can be optimally combined in oligometastatic non-small cell lung cancer (搜索), an intermediate disease state between localized and widely disseminated cancer.
Oligometastatic disease (搜索) is defined as up to five metastases in no more than three organs, a population with potentially more favorable tumor biology than widely metastatic disease.
The review addresses unresolved clinical dilemmas including whether to irradiate all metastatic sites or only selected or progressing lesions, and the optimal timing and duration of immunotherapy.
Non-small cell lung cancer (搜索) (NSCLC) remains the leading cause of cancer-related mortality worldwide, and a substantial proportion of patients present with stage IV disease, where the 5-year survival rate does not exceed 12%. Against that backdrop, a narrative review published in Contemporary Oncology focuses on oligometastatic disease (搜索) (OMD) — an intermediate state between localized and widely disseminated disease — and on how radiotherapy and immunotherapy should be balanced within it.
OMD is characterized by a limited number of metastases, defined in the most commonly used definition as a maximum of five lesions in not more than three organs, and is associated with potentially more favorable tumor biology. The concept traces back to the original oligometastases hypothesis advanced by Hellman and Weichselbaum in 1995 and revisited by the same authors in 2011, with subsequent consensus efforts from ESTRO-ASTRO, ESMO and EORTC refining how the entity is characterized and classified.
A Shifting Therapeutic Landscape
The treatment landscape for these patients has evolved significantly with the introduction of immune checkpoint inhibitors and chemo-immunotherapy, which have improved systemic disease control. In parallel, advances in local ablative therapies (LAT), including stereotactic body radiotherapy and surgery, have allowed for high local control rates with acceptable toxicity. Increasing evidence suggests a synergistic interaction between radiotherapy and immunotherapy, supporting combined treatment strategies — a paradigm shift described by Formenti and Demaria in 2013.
The review's stated aim is to address key clinical dilemmas in OMD management: whether all metastatic sites or only selected or progressing lesions should be treated, the optimal timing of radiotherapy in relation to immunotherapy, and the appropriate duration of immunotherapy. By commenting on current evidence alongside real-world clinical scenarios, the authors seek to provide a practical framework for individualized multimodal treatment strategies.
Local Consolidation: Trial Evidence
Several randomized studies underpin the rationale for local consolidation in limited metastatic NSCLC. The SABR-COMET phase II randomized trial reported long-term results for stereotactic ablative radiotherapy in the comprehensive treatment of oligometastatic cancers. Iyengar and colleagues conducted a phase 2 randomized clinical trial of consolidative radiotherapy for limited metastatic NSCLC, and Gomez et al. reported long-term results of a multi-institutional phase II randomized study comparing local consolidative therapy with maintenance therapy or observation in oligometastatic NSCLC.
More recently, NRG-LU002 — a randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for limited metastatic NSCLC — has reported results, and a systematic review and meta-analysis by Han et al. examined the efficacy and safety of local consolidative therapy combined with systemic therapy in driver-negative oligometastatic NSCLC.
Sequencing Radiotherapy With Checkpoint Blockade
The interaction between radiotherapy and PD-1 (搜索)/PD-L1 (搜索) blockade has been explored in both retrospective and prospective settings. A secondary analysis of the phase 1 KEYNOTE-001 trial by Shaverdian et al. examined previous radiotherapy and the clinical activity and toxicity of pembrolizumab in NSCLC. Theelen et al. published a pooled analysis of two randomized trials of pembrolizumab with or without radiotherapy for metastatic NSCLC, and Huang et al. reported in Nature Cancer that the combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold NSCLC.
In the oligometastatic setting specifically, Gao et al. reported results from a prospective multicenter observational study of early local therapy combined with PD-1 (搜索)/PD-L1 (搜索) inhibitors, while Lee et al. used recursive partitioning analysis to assess local ablative therapy combined with pembrolizumab in patients with synchronous oligometastatic NSCLC. The randomized phase 2 BOOSTER trial compared ablation plus immunotherapy versus immunotherapy alone in patients with advanced NSCLC who developed oligo-residual disease after anti-PD-1/L1 therapy.
Toxicity has also been a focus. Samuel et al. assessed the impact of radiotherapy on the efficacy and toxicity of anti-PD-1 (搜索) inhibitors in metastatic NSCLC, and the FORCE phase II trial (AIO/YMO-TRK-0415) reconsidered palliative radiotherapy in addition to PD-1 blockade. The review also cites ESMO guidance from Haanen et al. on the management of toxicities from immunotherapy.
Oligoprogression and Oligo-Residual Disease
A distinct clinical question concerns patients who progress at a limited number of sites while on immune checkpoint inhibitors. Mahmood et al. reported real-world, multinational outcomes following radiotherapy for oligoprogressive NSCLC on checkpoint inhibitors, and Santonja et al. conducted a retrospective study of radiotherapy for oligoprogressive disease in NSCLC treated with first-line pembrolizumab. The randomized, controlled phase 2 CURB study by Tsai et al. tested standard-of-care systemic therapy with or without stereotactic body radiotherapy in oligoprogressive breast cancer or NSCLC.
For oligo-residual disease after first-line chemo-immunotherapy, Chen et al. reported a single-arm phase 2 trial from China of consolidative stereotactic radiotherapy, and Xie et al. found that local consolidative therapy extended survival in metastatic NSCLC with oligo-residual disease following first-line immunotherapy, irrespective of PD-L1 (搜索) expression.
Ongoing Trials and Guideline Context
Multiple prospective studies continue to test these combinations, including a trial of standard maintenance therapy versus local consolidative radiation therapy plus maintenance therapy in oligometastatic NSCLC (NCT05278052), the randomized phase 3 NIRVANA-lung trial of PD-1 (搜索) inhibition plus chemotherapy with concurrent irradiation at varied tumor sites, a study of nivolumab and ipilimumab with or without local consolidation therapy in stage IV NSCLC (NCT03391869), a trial adding hypofractionated high-dose radiation in oligometastatic disease (搜索) (NCT06141070), and a study of first-line immunotherapy-based standard of care plus local ablative treatments in oligometastatic NSCLC (NCT06840782). A phase 2 study by Li et al. evaluated durvalumab combined with chemotherapy and SABR in oligometastatic NSCLC.
Guideline documents referenced in the review include the ASTRO/ESTRO clinical practice guideline on treatment of oligometastatic NSCLC, the ESMO Clinical Practice Guideline on non-oncogene-addicted metastatic NSCLC, and the NCCN Clinical Practice Guidelines on NSCLC (version 5.2026).
The Duration Question
The appropriate duration of immunotherapy remains unresolved. Pandey and Bhatti conducted a systematic review of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC. Rousseau et al. examined the impact of pembrolizumab treatment duration on overall survival in a nationwide retrospective cohort, and Sun et al. assessed the association between duration of immunotherapy and overall survival in advanced NSCLC. Geier et al. studied the duration of nivolumab in pretreated advanced NSCLC, while Elghawy et al. reported on late immune-related adverse events after at least two years of checkpoint inhibitor therapy and their association with survival.
The review also draws on experience from stage III disease, where durvalumab after chemoradiotherapy was established by Antonia et al. in the PACIFIC trial, and on broader questions of treatment sequencing, including work by Jongbloed et al. on the effect of treatment sequencing in NSCLC with a synchronous solitary extrathoracic metastasis. Remon et al. reviewed the state of the art and challenges in unresectable stage III NSCLC.
For clinicians, the review's contribution is a structured framework rather than a single new dataset: it maps the evidence for treating all versus selected lesions, for timing radiotherapy relative to immunotherapy, and for deciding how long to continue checkpoint blockade, while acknowledging that several of these questions remain open pending the readout of ongoing randomized trials.